content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on September 12, 2024</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>UNDER </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>THE SECURITIES ACT OF 1933 </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOMX INC.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact Name of Registrant as Specified in its
  Charter) </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><B>Delaware</B></TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><B>2836</B></TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><B>82-3364020</B></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction of</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>incorporation or organization)</B></P></TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Primary Standard Industrial</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Classification Code Number)</B></P></TD>
      <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(I.R.S. Employer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>708 Quince Orchard Rd, Suite 205 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gaithersburg, MD 20878</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(844) 972-0500<BR>
  (Address, including zip code,
  and telephone number, including area code, of Registrant&rsquo;s principal executive offices) </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED CHARDAN HEALTHCARE ACQUISITION
  CORP. LONG-TERM INCENTIVE PLAN</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Full title of the plans) </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Marina Wolfson</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BiomX Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>708 Quince Orchard Rd, Suite 205 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gaithersburg, MD 20878</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(844) 972-0500</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name, address, including zip code, and telephone
  number, including area code, of agent for service) </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copies to: </I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Howard E. Berkenblit</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sullivan &amp; Worcester LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Post Office Square</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boston, Massachusetts 02109</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(617) 338-2800</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large accelerated
  filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 30%">Large accelerated filer</TD>
      <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
      <TD STYLE="width: 20%">&nbsp;</TD>
      <TD STYLE="width: 30%">Accelerated filer</TD>
      <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Non-accelerated filer</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>Smaller reporting company</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Emerging growth company</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 2, 2020, BiomX Inc., or the Company, filed a Registration
  Statement on Form S-8 (File No. 333-235777), or, as amended, the Original Registration Statement, with the Securities and Exchange Commission,
  or the Commission, to register an aggregate of 100 shares of Common Stock of the Company that may be issued pursuant to the Chardan Healthcare
  Acquisition Corp. 2019 Omnibus Long-Term Incentive Plan, or the 2019 Plan, as well as 314,836 shares of Common Stock of the Company that
  may be issued pursuant to the 2015 Employee Stock Option Plan for Key Employees of BiomX Ltd., as amended.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2019 Plan was originally adopted by the Board on September 17,
  2019 and subsequently approved by our stockholders on October 23, 2019 and further amended on August 28, 2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As previously reported in connection with the merger agreement, or
  the Merger Agreement, entered into on March 6, 2024, by and among the Company, BTX Merger Sub I, Inc., BTX Merger Sub II, LLC and Adaptive
  Phage Therapeutics, Inc., on July 9, 2024, the Company&rsquo;s stockholders approved an amendment and restatement of the 2019 Plan, or
  the Amended Plan, pursuant to which shares of Common Stock equal to 15% of the fully-diluted outstanding equity interests of the Company
  immediately following the completion of the merger contemplated by the Merger Agreement (after giving effect to the conversion of the
  Series X Non-Voting Convertible Preferred Stock, par value $0.0001 per share to the Company&rsquo;s shares of Common Stock and the exercise
  of the warrants as described in the Proxy Statement filed with the Securities and Exchange Commission, or the SEC, on June 17, 2024) will
  be reserved for issuance to the Company&rsquo;s employees, directors, consultants and other service providers.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 26, 2024, the Company effected a one-for-ten (1:10) reverse
  stock split of its shares of Common Stock, or the Reverse Split, such that every ten (10) shares of Common Stock issued and outstanding
  as of August 26, 2024, were converted into one (1) share of Common Stock. All quantities of Common Stock and per share data presented herein
  give retroactive effect to the Reverse Split.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company is filing this Registration Statement on Form S-8 to register
  an additional 7,192,482 shares of Common Stock of the Company, such that an aggregate amount of 7,800,000 shares of Common Stock may be
  issued in connection with securities awards, which have been granted or may hereafter be granted under the Amended Plan. The 7,192,482
  shares of Common Stock of the Company being registered hereunder for the Amended Plan are comprised of: (i) 1,567,795 shares of Common
  Stock subject to awards granted on July 11, 2024; and (ii) 5,624,687 shares of Common Stock available for issuance.</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to General Instruction E to Form S-8, the contents of the
  Original Registration Statement are incorporated herein by reference, except for Item 3 and Item 8 of Part II of the Original Registration
  Statement, which are being updated by this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following documents filed with the Securities and Exchange Commission,
  or the Commission, by BiomX Inc., or the Registrant, pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act
  of 1934, as amended, or the Exchange Act, are hereby incorporated by reference in this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">The Registrant&rsquo;s Annual Report on <U STYLE="text-decoration: none"><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024030053/ea0202988-10k_biomx.htm">Form 10-K</A></U>
  for the year ended December 31, 2023, filed with the Commission on April 4, 2024;</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: left">The Registrant&rsquo;s Quarterly Reports on <U STYLE="text-decoration: none">Form 10-Q
  </U>for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024045273/ea0206522-10q_biomx.htm">March 31, 2024</A>, filed with the Commission on May 20, 2024, and for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024068981/ea0211083-10q_biomxinc.htm">June 30, 2024</A>, filed with
  the Commission on August 14, 2024;</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: left">The Registrant&rsquo;s Current Reports on Form 8-K filed
  on <U STYLE="text-decoration: none"><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/ea0201229-8k_biomx.htm">March 6, 2024</A></U> (Items 1.01 and 3.02 and exhibits 2.1, 3.1, 4.1, 4.2, 4.3, 10.1, 10.2, 99.1 and 99.2 only), <U STYLE="text-decoration: none"><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024023201/ea0201977-8k_biomx.htm">March 18, 2024</A>
  (as amended by </U>the Registrant&rsquo;s Current Reports on Form 8-K/A filed on <U STYLE="text-decoration: none"><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024024771/ea0202300-8ka1_bio.htm">March 21, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024048040/ea0207019-8ka1_biomx.htm">May 30, 2024</A>)</U>, <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024033032/ea0203936-8k_biomxinc.htm">April 15, 2024</A>,
  <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/ea020712501-8k_biomxinc.htm">May 30, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024060128/ea0209083-8k_biomx.htm">July 9, 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000101376224001812/ea0210175-8k_biomx.htm">July 29, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024070272/ea0211486-8k_biomx.htm">August 16, 2024</A>; and</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: left">The description of the Registrant&rsquo;s common stock, warrants
  and units contained in the Registration Statement on <U STYLE="text-decoration: none"><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000161577418014343/s114652_8a12b.htm">Form 8-A</A></U> filed on December 13, 2018, under the Exchange Act, as amended by
  <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024030053/ea020298801ex4-1_biomx.htm">Exhibit 4.1</A> the Registrant&rsquo;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024030053/ea0202988-10k_biomx.htm">Form 10-K</A> for the year ended December 31, 2023, and including any further amendment
  or report filed or to be filed for the purpose of updating such description.</TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All documents that the Registrant subsequently files pursuant to Sections
  13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective
  amendment to this Registration Statement indicating that all securities offered have been sold or which deregisters all securities then
  remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date
  of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed shall not be
  incorporated by reference into this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any statement contained in a document incorporated or deemed to be
  incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent
  that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference
  herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified
  or superseded, to constitute a part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed or incorporated by reference as part
  of this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="white-space: nowrap; vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify; width: 9%"><B>Exhibit No.</B></TD>
      <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
      <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; width: 90%"><B>Description</B></TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">4.1</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024068981/ea021108301ex3-1_biomxinc.htm"><U STYLE="text-decoration: none">Composite Copy of the Amended and Restated Certificate of Incorporation of BiomX Inc., as amended to date (Incorporated by reference to Exhibit 3.1 of BiomX Inc.&rsquo;s Quarterly Report on Form 10-Q filed with the Commission on August 14, 2024).</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">4.2</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390019021849/f8k1019ex3-3_biomx.htm"><U STYLE="text-decoration: none">Amended and Restated Bylaws of BiomX Inc. (incorporated by reference to Exhibit 3.3 of BiomX Inc.&rsquo;s Current Report on Form 8-K filed with the Commission on November 1, 2019).</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">4.3</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024020282/ea0201229ex3-1_biomx.htm"><U STYLE="text-decoration: none">Form of Certificate of Designation of Series X Preferred Stock (Incorporated by reference to Exhibit 3.1 of BiomX Inc.&rsquo;s Current Report on Form 8-K filed with the Commission on March 6, 2024).</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">5.1*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea021425101ex5-1_biomx.htm"><U STYLE="text-decoration: none">Opinion of Sullivan &amp; Worcester LLP</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">23.1*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea021425101ex23-1_biomx.htm"><U STYLE="text-decoration: none">Consent of Kesselman &amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited.</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">24.1*</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="#a_001"><U STYLE="text-decoration: none">Power of Attorney (included on the signature pages to this Registration Statement)</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">99.1</TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1739174/000121390024060128/ea0209083ex10-1_biomx.htm"><U STYLE="text-decoration: none">Amended and Restated Chardan Healthcare Acquisition Corp. Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 of the BiomX Inc.&rsquo;s Current Report on Form 8-K filed with the Commission on July 9, 2024)</U></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: white">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: #CCEEFF">
      <TD STYLE="text-align: justify">107*</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD><A HREF="ea021425101ex-fee_biomx.htm"><U STYLE="text-decoration: none">Filing Fee Table</U></A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in">*</TD>
      <TD STYLE="text-align: justify">Filed herewith.</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, the registrant
  certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this
  Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ness Ziona, Israel, on this 12 day
  of September, 2024.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">BIOMX INC.</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 4%">&nbsp;</TD>
      <TD STYLE="width: 36%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>By</TD>
      <TD STYLE="border-bottom: black 1.5pt solid">/s/ Jonathan Solomon</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Jonathan Solomon</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Chief Executive Officer</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes
  and appoints each of Mr. Jonathan Solomon and Ms. Marina Wolfson, and each or any one of them, as the undersigned&rsquo;s true and lawful
  attorneys-in-fact and agents, with full powers of substitution and resubstitution, for the undersigned and in the undersigned&rsquo;s
  name, place and stead, in any and all capacities, to sign any and all amendments (including pre-effective and post-effective amendments)
  to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities
  and Exchange Commission, granting unto such attorneys-in-fact and agents, full power and authority to do and perform each and every act
  and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or
  could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents, or their substitute or substitutes, may
  lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, this Registration
  Statement has been signed below by the following persons in the capacities and on the date indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center; border-bottom: black 1.5pt solid; width: 20%"><B>Signature</B></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; width: 58%; text-align: center"><B>Title</B></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 18%; text-align: center"><B>Date</B></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top">/s/ Russell Greig &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">Chairman of the Board of Directors</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Dr. Russell Greig &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom">/s/ Jonathan Solomon &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">Chief Executive Officer</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Jonathan Solomon &nbsp;&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>(Principal Executive Officer) and Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom">/s/ Marina Wolfson &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top">Chief Financial Officer</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Marina Wolfson &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>(Principal Financial Officer and Principal Accounting Officer)</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Susan Blum</TD>
      <TD>&nbsp;</TD>
      <TD>Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Susan Blum</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid">/s/ Jesse Goodman &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Dr. Jesse Goodman &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid">/s/ Jonathan Leff &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Jonathan Leff &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid">/s/ Gregory Merril &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Gregory Merril &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid">/s/ Alan Moses &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Dr. Alan Moses &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid">/s/ Eddie Williams &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>Director</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">September 12, 2024</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>Eddie Williams &nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-3</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  
  
  
  
  
  
  
  
  
  
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0214251-s8_biomxinc.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 38773}]
metadata_filer: {"company-data": {"conformed-name": "BiomX Inc.", "cik": "0001739174", "assigned-sic": "2836", "organization-name": "03 Life Sciences", "irs-number": "823364020", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-282059", "film-number": "241294923"}, "business-address": {"street1": "708 QUINCE ORCHARD RD", "street2": "SUITE 205", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "844-972-0500"}, "mail-address": {"street1": "708 QUINCE ORCHARD RD", "street2": "SUITE 205", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}, "former-company": {"former-conformed-name": "Chardan Healthcare Acquisition Corp.", "date-changed": "20180430"}}
text: As filed with the Securities and Exchange Commission
  on September 12, 2024
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  BIOMX INC.
  (Exact Name of Registrant as Specified in its
  Charter)
  Delaware
  2836
  82-3364020
  (State or other jurisdiction of
  incorporation or organization)
  (Primary Standard Industrial
  Classification Code Number)
  (I.R.S. Employer
  Identification No.)
  708 Quince Orchard Rd, Suite 205
  Gaithersburg, MD 20878
  (844) 972-0500
  (Address, including zip code,
  and telephone number, including area code, of Registrant's principal executive offices)
  AMENDED AND RESTATED CHARDAN HEALTHCARE ACQUISITION
  CORP. LONG-TERM INCENTIVE PLAN
  (Full title of the plans)
  Marina Wolfson
  BiomX Inc.
  708 Quince Orchard Rd, Suite 205
  Gaithersburg, MD 20878
  (844) 972-0500
  (Name, address, including zip code, and telephone
  number, including area code, of agent for service)
  Copies to:
  Howard E. Berkenblit
  Sullivan & Worcester LLP
  One Post Office Square
  Boston, Massachusetts 02109
  (617) 338-2800
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated
  filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act.
  ☐
  EXPLANATORY NOTE
  On January 2, 2020, BiomX Inc., or the Company, filed a Registration
  Statement on Form S-8 (File No. 333-235777), or, as amended, the Original Registration Statement, with the Securities and Exchange Commission,
  or the Commission, to register an aggregate of 100 shares of Common Stock of the Company that may be issued pursuant to the Chardan Healthcare
  Acquisition Corp. 2019 Omnibus Long-Term Incentive Plan, or the 2019 Plan, as well as 314,836 shares of Common Stock of the Company that
  may be issued pursuant to the 2015 Employee Stock Option Plan for Key Employees of BiomX Ltd., as amended.
  The 2019 Plan was originally adopted by the Board on September 17,
  2019 and subsequently approved by our stockholders on October 23, 2019 and further amended on August 28, 2023.
  As previously reported in connection with the merger agreement, or
  the Merger Agreement, entered into on March 6, 2024, by and among the Company, BTX Merger Sub I, Inc., BTX Merger Sub II, LLC and Adaptive
  Phage Therapeutics, Inc., on July 9, 2024, the Company's stockholders approved an amendment and restatement of the 2019 Plan, or
  the Amended Plan, pursuant to which shares of Common Stock equal to 15% of the fully-diluted outstanding equity interests of the Company
  immediately following the completion of the merger contemplated by the Merger Agreement (after giving effect to the conversion of the
  Series X Non-Voting Convertible Preferred Stock, par value $0.0001 per share to the Company's shares of Common Stock and the exercise
  of the warrants as described in the Proxy Statement filed with the Securities and Exchange Commission, or the SEC, on June 17, 2024) will
  be reserved for issuance to the Company's employees, directors, consultants and other service providers.
  On August 26, 2024, the Company effected a one-for-ten (1:10) reverse
  stock split of its shares of Common Stock, or the Reverse Split, such that every ten (10) shares of Common Stock issued and outstanding
  as of August 26, 2024, were converted into one (1) share of Common Stock. All quantities of Common Stock and per share data presented herein
  give retroactive effect to the Reverse Split.
  The Company is filing this Registration Statement on Form S-8 to register
  an additional 7,192,482 shares of Common Stock of the Company, such that an aggregate amount of 7,800,000 shares of Common Stock may be
  issued in connection with securities awards, which have been granted or may hereafter be granted under the Amended Plan. The 7,192,482
  shares of Common Stock of the Company being registered hereunder for the Amended Plan are comprised of: (i) 1,567,795 shares of Common
  Stock subject to awards granted on July 11, 2024; and (ii) 5,624,687 shares of Common Stock available for issuance.
  Pursuant to General Instruction E to Form S-8, the contents of the
  Original Registration Statement are incorporated herein by reference, except for Item 3 and Item 8 of Part II of the Original Registration
  Statement, which are being updated by this Registration Statement.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The following documents filed with the Securities and Exchange Commission,
  or the Commission, by BiomX Inc., or the Registrant, pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act
  of 1934, as amended, or the Exchange Act, are hereby incorporated by reference in this Registration Statement:
  (a)
  The Registrant's Annual Report on
  Form 10-K
  for the year ended December 31, 2023, filed with the Commission on April 4, 2024;
  (b)
  The Registrant's Quarterly Reports on
  Form 10-Q
  for the quarter ended
  March 31, 2024
  , filed with the Commission on May 20, 2024, and for the quarter ended
  June 30, 2024
  , filed with
  the Commission on August 14, 2024;
  (c)
  The Registrant's Current Reports on Form 8-K filed
  on
  March 6, 2024
  (Items 1.01 and 3.02 and exhibits 2.1, 3.1, 4.1, 4.2, 4.3, 10.1, 10.2, 99.1 and 99.2 only),
  March 18, 2024
  (as amended by
  the Registrant's Current Reports on Form 8-K/A filed on
  March 21, 2024
  and
  May 30, 2024
  )
  ,
  April 15, 2024
  ,
  May 30, 2024
  ,
  July 9, 2024
  ,
  July 29, 2024
  and
  August 16, 2024
  ; and
  (d)
  The description of the Registrant's common stock, warrants
  and units contained in the Registration Statement on
  Form 8-A
  filed on December 13, 2018, under the Exchange Act, as amended by
  Exhibit 4.1
  the Registrant's Annual Report on
  Form 10-K
  for the year ended December 31, 2023, and including any further amendment
  or report filed or to be filed for the purpose of updating such description.
  All documents that the Registrant subsequently files pursuant to Sections
  13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective
  amendment to this Registration Statement indicating that all securities offered have been sold or which deregisters all securities then
  remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date
  of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed shall not be
  incorporated by reference into this Registration Statement.
  Any statement contained in a document incorporated or deemed to be
  incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent
  that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference
  herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified
  or superseded, to constitute a part of this Registration Statement.
  II-
  1
  Item 8. Exhibits.
  The following exhibits are filed or incorporated by reference as part
  of this Registration Statement:
  Exhibit No.
  Description
  4.1
  Composite Copy of the Amended and Restated Certificate of Incorporation of BiomX Inc., as amended to date (Incorporated by reference to Exhibit 3.1 of BiomX Inc.'s Quarterly Report on Form 10-Q filed with the Commission on August 14, 2024).
  4.2
  Amended and Restated Bylaws of BiomX Inc. (incorporated by reference to Exhibit 3.3 of BiomX Inc.'s Current Report on Form 8-K filed with the Commission on November 1, 2019).
  4.3
  Form of Certificate of Designation of Series X Preferred Stock (Incorporated by reference to Exhibit 3.1 of BiomX Inc.'s Current Report on Form 8-K filed with the Commission on March 6, 2024).
  5.1*
  Opinion of Sullivan & Worcester LLP
  23.1*
  Consent of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited.
  24.1*
  Power of Attorney (included on the signature pages to this Registration Statement)
  99.1
  Amended and Restated Chardan Healthcare Acquisition Corp. Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 of the BiomX Inc.'s Current Report on Form 8-K filed with the Commission on July 9, 2024)
  107*
  Filing Fee Table
  *
  Filed herewith.
  II-
  2
  SIGNATURES
  Pursuant to the requirements of the Securities Act, the registrant
  certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this
  Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ness Ziona, Israel, on this 12 day
  of September, 2024.
  BIOMX INC.
  By
  /s/ Jonathan Solomon
  Jonathan Solomon
  Chief Executive Officer
  POWER OF ATTORNEY
  KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes
  and appoints each of Mr. Jonathan Solomon and Ms. Marina Wolfson, and each or any one of them, as the undersigned's true and lawful
  attorneys-in-fact and agents, with full powers of substitution and resubstitution, for the undersigned and in the undersigned's
  name, place and stead, in any and all capacities, to sign any and all amendments (including pre-effective and post-effective amendments)
  to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities
  and Exchange Commission, granting unto such attorneys-in-fact and agents, full power and authority to do and perform each and every act
  and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as the undersigned might or
  could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents, or their substitute or substitutes, may
  lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities Act, this Registration
  Statement has been signed below by the following persons in the capacities and on the date indicated.
  Signature
  Title
  Date
  /s/ Russell Greig
  Chairman of the Board of Directors
  September 12, 2024
  Dr. Russell Greig
  /s/ Jonathan Solomon
  Chief Executive Officer
  September 12, 2024
  Jonathan Solomon
  (Principal Executive Officer) and Director
  /s/ Marina Wolfson
  Chief Financial Officer
  September 12, 2024
  Marina Wolfson
  (Principal Financial Officer and Principal Accounting Officer)
  /s/ Susan Blum
  Director
  September 12, 2024
  Susan Blum
  /s/ Jesse Goodman
  Director
  September 12, 2024
  Dr. Jesse Goodman
  /s/ Jonathan Leff
  Director
  September 12, 2024
  Jonathan Leff
  /s/ Gregory Merril
  Director
  September 12, 2024
  Gregory Merril
  /s/ Alan Moses
  Director
  September 12, 2024
  Dr. Alan Moses
  /s/ Eddie Williams
  Director
  September 12, 2024
  Eddie Williams
  II-3